×
S&P 500   4,125.21 (+1.66%)
DOW   32,949.50 (+0.96%)
QQQ   306.87 (+2.52%)
AAPL   148.53 (+3.30%)
MSFT   271.40 (+2.07%)
FB   193.63 (+1.04%)
GOOGL   2,240.00 (+3.90%)
AMZN   2,263.48 (+1.89%)
TSLA   751.89 (+6.24%)
NVDA   185.93 (+4.16%)
BABA   93.14 (-1.42%)
NIO   16.36 (+2.06%)
AMD   100.72 (+1.99%)
CGC   4.89 (-11.89%)
MU   72.80 (+3.12%)
T   21.25 (-0.33%)
GE   77.71 (+0.91%)
F   13.48 (+2.74%)
DIS   108.13 (+2.39%)
AMC   13.45 (+9.98%)
PFE   53.67 (-0.59%)
PYPL   84.89 (+5.56%)
NFLX   194.17 (+1.45%)
S&P 500   4,125.21 (+1.66%)
DOW   32,949.50 (+0.96%)
QQQ   306.87 (+2.52%)
AAPL   148.53 (+3.30%)
MSFT   271.40 (+2.07%)
FB   193.63 (+1.04%)
GOOGL   2,240.00 (+3.90%)
AMZN   2,263.48 (+1.89%)
TSLA   751.89 (+6.24%)
NVDA   185.93 (+4.16%)
BABA   93.14 (-1.42%)
NIO   16.36 (+2.06%)
AMD   100.72 (+1.99%)
CGC   4.89 (-11.89%)
MU   72.80 (+3.12%)
T   21.25 (-0.33%)
GE   77.71 (+0.91%)
F   13.48 (+2.74%)
DIS   108.13 (+2.39%)
AMC   13.45 (+9.98%)
PFE   53.67 (-0.59%)
PYPL   84.89 (+5.56%)
NFLX   194.17 (+1.45%)
S&P 500   4,125.21 (+1.66%)
DOW   32,949.50 (+0.96%)
QQQ   306.87 (+2.52%)
AAPL   148.53 (+3.30%)
MSFT   271.40 (+2.07%)
FB   193.63 (+1.04%)
GOOGL   2,240.00 (+3.90%)
AMZN   2,263.48 (+1.89%)
TSLA   751.89 (+6.24%)
NVDA   185.93 (+4.16%)
BABA   93.14 (-1.42%)
NIO   16.36 (+2.06%)
AMD   100.72 (+1.99%)
CGC   4.89 (-11.89%)
MU   72.80 (+3.12%)
T   21.25 (-0.33%)
GE   77.71 (+0.91%)
F   13.48 (+2.74%)
DIS   108.13 (+2.39%)
AMC   13.45 (+9.98%)
PFE   53.67 (-0.59%)
PYPL   84.89 (+5.56%)
NFLX   194.17 (+1.45%)
S&P 500   4,125.21 (+1.66%)
DOW   32,949.50 (+0.96%)
QQQ   306.87 (+2.52%)
AAPL   148.53 (+3.30%)
MSFT   271.40 (+2.07%)
FB   193.63 (+1.04%)
GOOGL   2,240.00 (+3.90%)
AMZN   2,263.48 (+1.89%)
TSLA   751.89 (+6.24%)
NVDA   185.93 (+4.16%)
BABA   93.14 (-1.42%)
NIO   16.36 (+2.06%)
AMD   100.72 (+1.99%)
CGC   4.89 (-11.89%)
MU   72.80 (+3.12%)
T   21.25 (-0.33%)
GE   77.71 (+0.91%)
F   13.48 (+2.74%)
DIS   108.13 (+2.39%)
AMC   13.45 (+9.98%)
PFE   53.67 (-0.59%)
PYPL   84.89 (+5.56%)
NFLX   194.17 (+1.45%)
NASDAQ:INMB

INmune Bio (INMB) Stock Forecast, Price & News

$6.93
+0.60 (+9.48%)
(As of 05/27/2022 11:32 AM ET)
Add
Compare
Today's Range
$6.47
$6.93
50-Day Range
$5.48
$9.14
52-Week Range
$4.63
$30.37
Volume
4,709 shs
Average Volume
154,230 shs
Market Capitalization
$124.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.44
30 days | 90 days | 365 days | Advanced Chart
Receive INMB News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

INmune Bio logo

About INmune Bio

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Headlines

INmune Bio (NASDAQ:INMB) PT Lowered to $14.00
INmune Bio's (INMB) "Buy" Rating Reaffirmed at B. Riley
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INMB
Fax
N/A
Employees
10
Year Founded
N/A

Sales & Book Value

Annual Sales
$180 thousand
Book Value
$4.22 per share

Profitability

Net Income
$-30.34 million
Pretax Margin
-9,613.82%

Debt

Price-To-Earnings

Miscellaneous

Free Float
8,273,000
Market Cap
$124.37 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/27/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.13 out of 5 stars

Medical Sector

453rd out of 1,424 stocks

Biological Products, Except Diagnostic Industry

73rd out of 209 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













INmune Bio (NASDAQ:INMB) Frequently Asked Questions

Is INmune Bio a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INmune Bio stock.
View analyst ratings for INmune Bio
or view top-rated stocks.

When is INmune Bio's next earnings date?

INmune Bio is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for INmune Bio
.

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) issued its quarterly earnings results on Thursday, May, 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.21. During the same quarter in the previous year, the business earned ($0.32) earnings per share.
View INmune Bio's earnings history
.

What price target have analysts set for INMB?

3 brokerages have issued 1-year price targets for INmune Bio's stock. Their forecasts range from $7.00 to $22.00. On average, they anticipate INmune Bio's stock price to reach $14.33 in the next twelve months. This suggests a possible upside of 106.8% from the stock's current price.
View analysts' price targets for INmune Bio
or view top-rated stocks among Wall Street analysts.

Who are INmune Bio's key executives?
INmune Bio's management team includes the following people:
What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).

What is INmune Bio's stock symbol?

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

Who are INmune Bio's major shareholders?

INmune Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.08%), Royal Bank of Canada (0.29%), State Street Corp (0.21%), Advisor Group Holdings Inc. (0.19%), Westside Investment Management Inc. (0.15%) and Fermata Advisors LLC (0.11%). Company insiders that own INmune Bio stock include David J Moss, Mark William Lowdell, Raymond Joseph Tesi and Timothy J Schroeder.
View institutional ownership trends for INmune Bio
.

Which major investors are selling INmune Bio stock?

INMB stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc.. Company insiders that have sold INmune Bio company stock in the last year include David J Moss, Mark William Lowdell, Raymond Joseph Tesi, and Timothy J Schroeder.
View insider buying and selling activity for INmune Bio
or view top insider-selling stocks.

Which major investors are buying INmune Bio stock?

INMB stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Westside Investment Management Inc., Simplex Trading LLC, Royal Bank of Canada, State Street Corp, Fermata Advisors LLC, and Group One Trading L.P..
View insider buying and selling activity for INmune Bio
or or view top insider-buying stocks.

How do I buy shares of INmune Bio?

Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is INmune Bio's stock price today?

One share of INMB stock can currently be purchased for approximately $6.93.

How much money does INmune Bio make?

INmune Bio has a market capitalization of $124.37 million and generates $180 thousand in revenue each year. The company earns $-30.34 million in net income (profit) each year or ($1.930010) on an earnings per share basis.

How many employees does INmune Bio have?

INmune Bio employs 10 workers across the globe.

What is INmune Bio's official website?

The official website for INmune Bio is www.inmunebio.com.

How can I contact INmune Bio?

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at (858) 964-3720 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.